The Silence Therapeutics acquisition gives Merck KGaA a drug ready for a pivotal test in the blood disorder polycythemia vera ...

AdvaMed CEO Scott Whitaker outlined four policy priorities at the MedTech Conference: tariffs, FDA user fees, payment and coverage, and cybersecurity.

Some of the thorniest problems in medicine that AI can improve have nothing to do with diagnosis. They have to do with triage ...

OMass’s molecule is vying to become an alternative to a Neurocrine Biosciences drug that is currently the only FDA-approved ...

An Aardvark Therapeutics clinical trial that has been on voluntary pause for nearly three months due to a safety signal is now formally under an FDA clinical hold, and the biotech said it will unblind ...

Outro’s funding included participation from Listen Ventures, Cake Ventures, Jason Calicanis’s LAUNCH, Actions Capital, Hannah ...

The Series A round was led by Oak HC/FT, with participation from Norwest, .406 Ventures, Constellation Ventures, Y Combinator ...

City Therapeutics’ lead RNA interference therapy could become an alternative to blockbuster-selling anticoagulants. The ...

HealthTap launched a virtual care program to support sleep equipment suppliers and patients using PAP therapy.

Cybersecurity leaders discussed how AI-driven cybersecurity attacks pose a new level of risk for hospitals and health systems ...

Earlier detection is valuable, but it creates a duty that does not end when an alert appears in the electronic health record.

Diagnostics and drug development startup Arboretum LifeSciences launched with $30 million in financing. Its executives say ...